淋巴浆细胞淋巴瘤/华氏巨球蛋白血症患者死因分析(2000-2016)
基于美国17个癌症登记处7289例新发LPL/WM患者(2000-2016),分析3132例死亡原因。16年累积死亡率随年龄增长而升高,非癌症死亡风险较一般人群高20%,主要源于感染、呼吸和消化系统疾病,诊断后1年内风险最高。
要点
- 感染、呼吸和消化系统疾病死亡风险显著升高,心血管疾病无超额死亡。
核心结论
- LPL/WM患者非癌症死亡风险较一般人群高20%,主要归因于感染、呼吸和消化系统疾病,诊断后1年内风险最高。
研究设计与样本
- 基于美国17个基于人群的癌症登记处,识别2000-2016年诊断为第一原发LPL(n=3108)或WM(n=4181)的7289例成人患者。
- 基于3132例死亡分析死因别死亡率,计算标准化死亡比(SMR)及95%置信区间(CI)。
临床怎么用
- 对LPL/WM患者应加强感染、呼吸和消化系统疾病的监测与预防,尤其在诊断后1年内。
- 长期生存者需警惕MDS/AML及实体瘤的发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Data on cause-specific mortality after lymphoplasmacytic lymphoma (LPL) and Waldenström macroglobulinaemia (WM) are lacking. We identified causes of death amongst 7289 adults diagnosed with incident first primary LPL (n = 3108) or WM (n = 4181) during 2000-2016 in 17 USA population-based cancer registries. Based on 3132 deaths, 16-year cumulative mortality was 23·2% for lymphomas, 8·4% for non-lymphoma cancers and 14·7% for non-cancer causes for patients aged <65 years at diagnosis of LPL/WM, versus 33·4%, 11·2% and 48·7%, respectively, for those aged ≥75 years. Compared with the general population, patients with LPL/WM had a 20% higher risk of death due to non-cancer causes (n = 1341 deaths, standardised mortality ratio [SMR] 1·2, 95% confidence interval [CI] 1·1-1·2), most commonly from infectious (n = 188; SMR 1·8, 95% CI 1·6-2·1), respiratory (n = 143; SMR 1·2, 95% CI 1·0-1·4), and digestive (n = 80; SMR 1·8, 95% CI 1·4-2·2) diseases, but no excess mortality from cardiovascular diseases (n = 477, SMR 1·1, 95% CI 1·0-1·1). Risks were highest for non-cancer causes within 1 year of diagnosis (n = 239; SMR<1year 1·3, 95% CI 1·2-1·5), declining thereafter (n = 522; SMR≥5years 1·1, 95% CI 1·1-1·2). Myelodysplastic syndrome/acute myeloid leukaemia deaths were notably increased (n = 46; SMR 4·4, 95% CI 3·2-5·9), whereas solid neoplasm deaths were only elevated among ≥5-year survivors (n = 145; SMR≥5years 1·3, 95% CI 1·1-1·5). This work identifies new areas for optimising care and reducing mortality for patients with LPL/WM.
引用
- Dalal NH, Dores GM, Curtis RE, et al. Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016. Br J Haematol. 2020. PMID: 32090327. doi:10.1111/bjh.16492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。